Britain trials new cell therapy for multiple sclerosis

Britain is trialing a new cell therapy for multiple sclerosis, potentially halting disease progression after a single infusion. The experimental treatment, CAR T-therapy, modifies a patient's own T-cells to target and destroy immune cells that attack the nervous system. Emily Genders, 37, is the first patient to receive the infusion. This therapy has shown success in treating certain blood cancers and is now being tested for autoimmune disorders, offering hope for a breakthrough in MS treatment.